Sourcing Indian Generic Medicines into Saudi Arabia: How SFDA, Your Local Agent, and NUPCO Fit Together

Understanding the split between SFDA registration, your local Saudi agent, and NUPCO listing early saves a lot of confusion later. Saudi Arabia is one of the largest pharmaceutical markets in the Gulf, and it runs more than one gate before an imported generic can be sold and then procured by a government hospital. This is how those gates fit together, written from the position of a sourcing house that supplies product and documentation, not a manufacturer and not your Saudi licence holder.

Where M Care fits, and where it does not.

M Care Exports is an India-based pharmaceutical merchant-exporter. We are a sourcing and trading house, not a manufacturer. We do not own the plants that make the medicines, and we do not hold a Saudi registration. What we do is supply WHO-GMP finished product from qualified Indian manufacturers, pull together the dossier and CTD documentation a registration needs, and work alongside your local Saudi agent so the regulatory file can be built and filed in the Kingdom. This guide is written from that honest position.

Below we walk through the four things that actually decide whether your product can be sold and procured in Saudi Arabia: SFDA marketing authorisation and who holds it, NUPCO supplier registration and catalogue listing as a separate step, the Vision 2030 local-content rules that quietly disadvantage pure imports, and the documentation, labelling and pricing set you have to assemble. Where the public record is unclear or evolving, we say so rather than guessing.

SFDA registration, and why the authorisation never sits with the Indian factory.

To legally market an imported generic medicine in Saudi Arabia, the product has to obtain Marketing Authorization, the registration granted by the Saudi Food and Drug Authority (SFDA). The SFDA is the body that regulates pharmaceutical products in the Kingdom and sets the registration and post-marketing requirements. No SFDA registration means the product cannot be placed on the Saudi market, full stop, and SFDA clearance is a prerequisite before any government procurement route opens.

Before a single product application is filed, the establishment behind it has to be on file. Local and international companies, manufacturers, agents and wholesale distributors first register in the SFDA Drug Establishments National Registry (DENR), an electronic system that builds a national database of drug establishments. DENR registration provides the login credentials needed to access SFDA electronic drug services and to start the Saudi Drug Registration process. It helps to read DENR as a registry, a national database of entities registered or licensed in the Kingdom, rather than as a licence in itself. Holding DENR access is not the same as holding an SFDA establishment licence, which is a separate status worth confirming directly.

Here is the part most buyers underestimate. A foreign manufacturer in India cannot submit a registration application directly to the SFDA. It has to appoint a local authorised representative or authorised local agent inside Saudi Arabia, and that local entity is the one that handles regulatory submissions, communication with the SFDA, pharmacovigilance and safety monitoring, and ongoing compliance. The Saudi authorised representative must be a legally registered entity in the Kingdom. It acts as the regulatory point of contact, receives official SFDA correspondence, and is accountable for post-approval obligations on behalf of the foreign company across the product lifecycle.

Who formally owns the Marketing Authorization Holder (MAH) status, the legal owner of the authorisation in Saudi Arabia, depends on the submission pathway chosen. Regulatory-affairs advisers generally recommend keeping the MA under the manufacturer's own SFDA account rather than a distributor's, but that is consultancy practice, not a fixed SFDA rule, and you should decide it deliberately rather than by accident. International companies are reported to have several routes into the system: establishing a local legal entity through the Ministry of Investment (MISA), setting up a scientific office for direct submissions, submitting through a local distributor on a shared SFDA account, or using an SFDA-approved local consulting firm running a dedicated account. Treat these as reported pathways from advisory sources and confirm the current options against the live SFDA position.

WHO-GMP product plus dossier, working through your agent.

Given all of that, an Indian merchant-exporter has a clear and limited role, and it is worth being precise about it. M Care does not hold the Saudi authorisation, does not become your MAH, and does not replace the local agent the SFDA requires. What we supply is the finished product from WHO-GMP manufacturing and the dossier and CTD support that the registration file is built from. We work with and through the Saudi authorised agent or distributor you appoint, rather than around them.

Manufacturing sites that supply SFDA-registered drugs are subject to GMP requirements. The SFDA applies a risk-based approach here: a physical site inspection (with inspection fees) may be required, but a valid GMP certificate from a recognised authority such as the EMA, US FDA or ANVISA can be accepted in place of an on-site inspection. The base requirement is straightforward, a valid GMP certificate should be submitted, and the waiver mechanics around recognised authorities and GCC frameworks are described by advisory sources rather than quoted regulation. Our part is to source from manufacturers whose GMP status and certificates stand up to that scrutiny.

Generic-product applications are submitted electronically in eCTD (Common Technical Document) format through the SFDA portal, and bioequivalence study data is a standard requirement for generic products. Where the reference product is not already registered with the SFDA, the dossier also has to carry a comprehensive literature review of the active substance in Module 2.5 (Clinical Overview). These are the pieces an Indian sourcing house helps assemble from the supply side: the eCTD-ready modules, the bioequivalence data, the manufacturing and quality documentation, handed to your local agent to file under their SFDA access. The fast-track Verification and Abridged routes, by the way, are not available for generics; they apply only to new chemical entities and new biologics, so a generic file follows the standard route.

NUPCO: a second, separate registration before you can sell to government.

SFDA registration gets a product onto the market. It does not, on its own, get it into a government hospital. That is the single most common misread we see from first-time buyers. Selling into the Saudi public health system runs through NUPCO, the National Unified Procurement Company, and registering with NUPCO is a distinct step from SFDA registration, with its own portal and its own requirements.

NUPCO was established in 2009 by Royal Decree with a registered capital of SAR 1.5 billion and is fully owned by the Public Investment Fund (PIF). It is the largest centralized company in Saudi Arabia for the procurement, logistics, warehousing and distribution of medication, medical devices and supplies for the government health sector, serving public-sector health entities including the Ministry of Health and other government health authorities. It maintains a Unified Catalogue, an electronic guide of medicines, devices and supplies with regularly updated technical specifications and pricing references, used across government health agencies.

Two things have to happen here that SFDA registration does not cover. First, suppliers must register with NUPCO before bidding on its tenders, through NUPCO's supplier-registration portal, which asks for standard company details including a Saudi Commercial Registration (CR) number and SFDA status. Second, a product must actually be listed in NUPCO's Unified Catalogue to be procurable by government hospitals. Products that are not in the catalogue are generally unavailable through government procurement channels, which makes catalogue inclusion a commercial requirement that sits on top of SFDA registration, not inside it. In short, SFDA registration is the prerequisite, not the finish line; NUPCO supplier registration plus catalogue listing are additionally required to win government tenders.

A few practical notes. An approved SFDA pharmaceutical marketing authorisation is valid for five years from the date of authorisation, with renewal required ahead of expiry; the renewal window opens around 180 days before expiry, and the SFDA does not provide a grace period once a registration lapses, so the local agent has to track this. NUPCO also runs additional platforms, including a digital healthcare Marketplace and the Wasfaty service that routes government prescriptions to private community pharmacies. Some secondary write-ups put NUPCO's annual procurement somewhere in the region of SAR 21 to 25 billion and describe multi-year Framework Agreements organised by therapeutic area as a primary procurement mechanism, but those figures and mechanics come from consultancy sources rather than a primary NUPCO disclosure, so treat them as approximate and confirm the current mechanism with NUPCO directly.

Vision 2030 local content: why a pure import competes uphill.

This is the part that changes the commercial maths, and it is worth understanding before you commit to a pure import-and-distribute model. Saudi Arabia runs a government-procurement local-content preference system administered by the Local Content and Government Procurement Authority (LCGPA), applying across public-sector buying including health. It has two core instruments: a Mandatory List of national products that covered government entities and their contractors must buy locally, and a price-preference mechanism that treats a qualifying local product as the lowest bid when its price is within a set margin of the cheapest offer.

The standard local-content price preference is 10 percent. A qualifying national product priced within 10 percent of the lowest offer is treated as the lowest bid in a government tender. (During COVID-19 this was temporarily raised to a maximum of 30 percent by sector standards, then reverted to 10 percent.) For medicines specifically, the LCGPA pharmaceutical-sector initiative adds a preference of up to 20 percent on top of the standard 10, so a qualifying local product can carry a combined edge of up to around 30 percent versus foreign products: 10 percent for being on the initiative list, plus a further up to 10 percent where the product contains a domestically manufactured Active Pharmaceutical Ingredient (API).

The eligibility rules are where pure imports lose ground. To qualify for the additional pharmaceutical preference, a product needs a valid SFDA registration certificate, and it is not eligible if it has undergone only secondary packaging in Saudi Arabia, unless it also contains a locally manufactured API or has had clinical or bioequivalence studies carried out in Saudi Arabia. In healthcare the LCGPA Mandatory List is reported to include about 623 pharmaceutical and medical-device items from roughly 90 manufacturers, items that covered government entities have to buy locally. NUPCO is the central buyer that operates inside this framework, while the LCGPA price-preference and Mandatory-List rules are the formal instruments.

The plain implication for an Indian exporter is this. A finished-goods import that is registered with the SFDA can compete in NUPCO tenders, but it competes without local-content preference, it is excluded from the Mandatory List, and it does not qualify for the additional pharma preference. It can therefore be beaten by a qualifying local product priced meaningfully higher. Local presence sits on a spectrum: secondary packaging alone is the weakest and does not by itself earn the additional preference; local fill-finish combined with local API or Saudi bioequivalence studies qualifies; and full local manufacturing maximises both procurement preference and certain SFDA pricing advantages. That spectrum is analysis drawn from the LCGPA and SFDA rules together, and it is the honest frame for deciding whether a pure-import play fits your volumes or whether you should be planning a local-content step over time. We do not publish specific Vision 2030 localisation-percentage targets because the public sources conflict and none is cleanly attributable to an official document.

The documentation, labelling and pricing set you have to assemble.

The registration file itself is structured, and the current governing guidance is the SFDA document Data Requirements for Human Drugs Submission, Version 4.0, issued 3 August 2025. The dossier goes in as eCTD/CTD. Module 1 (Regional Administrative Information) carries the cover letter, application form, product information (SmPC, labelling, the patient information leaflet, artwork mock-ups and samples), pharmacovigilance, certificates and pricing. One important update under Version 4.0: a Certificate of Pharmaceutical Product (CPP) or free-sales certificate is now optional and no longer required for new Marketing Authorization applications across all regulatory pathways. If you are working from older guidance that lists the CPP as mandatory, that requirement was reversed. A valid GMP certificate, on the other hand, should still be submitted in Module 1.7.

Arabic-language patient information is mandatory. The leaflet has to be provided as both an Arabic and an English version, alongside the SmPC, labelling and artwork. On secondary (outer) packaging, regulatory-affairs guidance describes a fairly detailed requirement set: product name in Arabic and English on more than three non-opposing faces of the box, the active substance qualitatively and quantitatively, pharmaceutical form and contents, route of administration, special warnings such as keep out of sight and reach of children, storage conditions, and the manufacturer and MAH name and address, with all excipients stated for parenteral, topical, eye or inhalation products. On primary packaging such as blisters and strips, the product name and strength, the MAH or brand name, manufacturing and expiry dates and the batch number are expected, and once labelling is SFDA-approved it must not be altered. The generic INN name is reported to be required at a size at least 50 percent of the trade name, a point that appears across regulatory-affairs sources rather than in the official text we reviewed, so treat it as practitioner guidance.

Saudi Arabia also operates a barcoding and traceability regime that your manufacturer has to meet. For market distribution the SFDA requires a GTIN-14 encoded in a GS1 DataMatrix barcode carrying, at minimum, the GTIN, expiry date and batch or lot number, with companies registering with GS1 Saudi Arabia to obtain a GS1 Company Prefix and generate GTINs. The Kingdom runs a national track-and-trace system, RSD or Rassd, under the SFDA, which is GTIN- and serial-number-based, and stakeholders need a unique Global Location Number (GLN). These are upstream obligations that a sourcing house and manufacturer prepare for, with the local agent handling the Saudi-side registrations.

Pricing is approved before market entry, and it is its own exercise. The SFDA uses a hybrid method: Internal Reference Pricing against comparable registered alternatives, External Reference Pricing against a basket of comparator countries, plus pharmacoeconomic input and price negotiation. The published rules list around 16 reference countries (a basket narrowed over time from 30 to 20 and then to 16). A price certificate, Form 16, documents ex-factory, CIF and public or retail prices and is checked against lower prices in reference markets. Generic ceiling prices are tiered below the originator: the first generic at a maximum of 70 percent, the second at 65 percent, and the third and subsequent at 60 percent, with the innovator price reduced 25 percent on first generic entry. For government procurement, the CIF price determined by the SFDA, without profit margin, is the ceiling for tendering and the starting point for negotiated reductions through NUPCO. We do not quote specific SFDA registration timelines or government fees as fact, because we could not locate an official, dated service-level or fee schedule; consultancy estimates exist but they vary and should not be read as a published standard.

FAQ

Does M Care Exports hold the SFDA registration for the products it supplies?

No. M Care is an India-based merchant-exporter and does not hold Saudi marketing authorisations. The SFDA marketing authorisation is held through a locally registered Saudi authorised agent or distributor that you appoint, since a foreign manufacturer cannot submit a registration application directly. M Care supplies the WHO-GMP finished product and the dossier and CTD support, and works with and through that local agent.

Is SFDA registration enough to sell into Saudi government hospitals?

No. SFDA registration is the prerequisite, not the finish line. To sell into the public health system you also have to register as a supplier with NUPCO and get the product listed in NUPCO's Unified Catalogue. Both are separate steps from SFDA registration, and a product that is not in the catalogue is generally not procurable through government channels.

Who needs to be appointed in Saudi Arabia, and what do they do?

A foreign manufacturer must appoint a local authorised representative or agent that is a legally registered entity in Saudi Arabia. That agent handles regulatory submissions, communication with the SFDA, pharmacovigilance and safety monitoring, receives official SFDA correspondence, and is accountable for post-approval obligations across the product lifecycle. M Care supplies product and documentation to support that agent, rather than replacing them.

Why does a pure import compete at a disadvantage in NUPCO tenders?

Saudi Arabia runs a local-content preference system under the LCGPA. A qualifying national product priced within 10 percent of the lowest offer is treated as the lowest bid, and medicines can carry an additional preference of up to 20 percent. A pure finished-goods import that is only SFDA-registered competes without that preference and is excluded from the Mandatory List, so it can be beaten by a qualifying local product priced meaningfully higher.

Is a CPP (Certificate of Pharmaceutical Product) still required for the dossier?

Under the current SFDA guidance, Data Requirements for Human Drugs Submission Version 4.0 issued 3 August 2025, submission of a CPP or free-sales certificate is optional and no longer required for new Marketing Authorization applications across all regulatory pathways. A valid GMP certificate, however, is still expected in the dossier. If you are working from older guidance that lists the CPP as mandatory, that requirement was reversed.

Does the manufacturing site always need an SFDA inspection?

Not necessarily. The SFDA applies a risk-based approach to GMP. A physical site inspection with fees may be required, but a valid GMP certificate from a recognised authority such as the EMA, US FDA or ANVISA can be accepted in place of an on-site inspection. M Care sources from WHO-GMP manufacturers whose certificates are intended to stand up to that review.

What is the documentation and labelling set in practice?

The dossier is submitted in eCTD/CTD format and, for generics, includes bioequivalence data. Labelling requires both Arabic and English patient leaflets, with detailed outer and primary packaging content, and a GS1 GTIN-14 DataMatrix barcode for traceability under the SFDA's RSD track-and-trace system. Pricing is approved before market entry via Internal and External Reference Pricing and a Form 16 price certificate, with generics tiered below the originator price.

Can you tell me the exact timelines and government fees for SFDA registration?

We do not state specific SFDA registration timelines or government fees as fact, because we could not locate an official, dated service-level or fee schedule to cite. Consultancy estimates circulate, but they vary by source and should not be treated as a published standard. Your appointed local agent is the right party to confirm current timelines and fees directly with the SFDA for your specific product and pathway.